Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651640 | 0.87 | F10 (0.66) | F10F2 | |
| SCHEMBL1675122 | 0.86 | F10 (1.00) | F10F2 | |
| SCHEMBL1654297 | 0.85 | F10 (0.64) | F10F2 | |
| SCHEMBL1381138 | 0.85 | F10 (0.67) | F10F2 | |
| SCHEMBL8358964 | 0.84 | F10 (0.86) | F10F2 | |
| SCHEMBL3241390 | 0.84 | F10 (0.80) | F10F2 | |
| Bromide SCHEMBL3240928 | 0.83 | F10 (0.79) | F10F2 | |
| SCHEMBL1675374 | 0.81 | F10 (0.81) | F10F2 | |
| SCHEMBL1456805 | 0.80 | F10 (0.66) | F10F2 | |
| SCHEMBL1675245 | 0.79 | F10 (0.78) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633746-B1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-07-28 | — | — | EP | disclosed |
| US-7196103-B2 | Indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| EP-1633746-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| US-20050033049-A1 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-10 | — | — | US | disclosed |
| WO-2004101554-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033049-A1 | Indole derivatives as factor Xa inhibitors | TFPI, TFPI2, F2 | F10 10/4885F2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.